Drugs / rDEN2/4delta30(ME)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00458120 | Mar 2007 → Aug 2008 | Dengue hemorrhagic fever | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rDEN2/4delta30(ME) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00458120 ↗ |
| Modality | Vaccine | “Live attenuated 10\^3 dose of rDEN2/4delta30(ME) vaccine.” NCT00458120 ↗ |
| Route | Subcutaneous | “Participants previously vaccinated with rDEN4delta30 will receive one subcutaneous vaccination (10\^3 dose of vaccine) of rDEN2/4delta30(ME) into the deltoid region of either arm.” NCT00458120 ↗ |